← Back to Screener
Pacific Biosciences of California, Inc. (PACB)
Price$1.63
Favorite Metrics
Price vs S&P 500 (26W)1.97%
Price vs S&P 500 (4W)14.48%
Market Capitalization$483.20M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)4.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.64%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-17.08%
Gross Margin (TTM)33.97%
Net Profit Margin (TTM)-341.47%
EPS (TTM)$-1.83
10-Day Avg Trading Volume5.53M
EPS Excl Extra (TTM)$-1.83
Revenue Growth (5Y)15.19%
EPS (Annual)$-1.82
ROI (Annual)-83.96%
Gross Margin (Annual)31.22%
Net Profit Margin (5Y Avg)-215.87%
Cash / Share (Quarterly)$0.93
Revenue Growth QoQ (YoY)13.82%
ROA (Last FY)-69.68%
Revenue Growth TTM (YoY)3.89%
EBITD / Share (TTM)$-1.78
ROE (5Y Avg)-2079.63%
Operating Margin (TTM)-346.15%
Cash Flow / Share (Annual)$-0.39
P/B Ratio90.33x
P/B Ratio (Quarterly)105.55x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)5.31x
Net Interest Coverage (TTM)-77.52x
ROA (TTM)-66.76%
EV / EBITDA (TTM)23.52x
EPS Incl Extra (Annual)$-1.82
Current Ratio (Annual)5.15x
Quick Ratio (Quarterly)4.32x
3-Month Avg Trading Volume6.71M
52-Week Price Return21.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.07
P/S Ratio (Annual)3.02x
Asset Turnover (Annual)0.20x
52-Week High$2.73
Operating Margin (5Y Avg)-232.44%
EPS Excl Extra (Annual)$-1.82
CapEx CAGR (5Y)49.30%
26-Week Price Return5.96%
Quick Ratio (Annual)4.32x
13-Week Price Return-20.40%
Total Debt / Equity (Annual)120.65x
Current Ratio (Quarterly)5.15x
Enterprise Value$849.073
Revenue / Share Growth (5Y)3.42%
Asset Turnover (TTM)0.20x
Book Value / Share Growth (5Y)-60.07%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-341.28%
Cash / Share (Annual)$0.93
3-Month Return Std Dev81.12%
Gross Margin (5Y Avg)34.06%
Net Income / Employee (TTM)$-1
ROE (Last FY)-10214.54%
Net Interest Coverage (Annual)-77.52x
EPS Basic Excl Extra (Annual)$-1.82
Receivables Turnover (TTM)5.08x
Total Debt / Equity (Quarterly)120.65x
EPS Incl Extra (TTM)$-1.83
Receivables Turnover (Annual)5.08x
ROI (TTM)-78.68%
P/S Ratio (TTM)3.02x
Pretax Margin (5Y Avg)-231.29%
Revenue / Share (Annual)$0.53
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)-8.62%
Year-to-Date Return-14.44%
5-Day Price Return18.52%
EPS Normalized (Annual)$-1.82
ROA (5Y Avg)-27.73%
Net Profit Margin (Annual)-341.47%
Month-to-Date Return21.21%
Cash Flow / Share (TTM)$-1.22
EBITD / Share (Annual)$-1.78
Operating Margin (Annual)-346.15%
LT Debt / Equity (Annual)120.65x
ROI (5Y Avg)-32.46%
LT Debt / Equity (Quarterly)120.65x
EPS Basic Excl Extra (TTM)$-1.83
P/TBV (Quarterly)19.27x
P/B Ratio (Annual)105.55x
Inventory Turnover (TTM)1.96x
Pretax Margin (TTM)-341.28%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-21.09%
Beta2.48x
P/FCF (Annual)26.18x
Revenue / Share (TTM)$0.53
ROE (TTM)-1123.27%
52-Week Low$0.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.81
3.73
3.81
3.75
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PACBPacific Biosciences of California, Inc. | 3.02x | 15.19% | 33.97% | -346.15% | $1.63 |
AAgilent Technologies Inc. | 4.74x | 5.41% | 52.60% | 20.40% | $118.25 |
WATWaters Corp | 10.04x | 6.00% | 59.28% | 25.36% | $319.04 |
MTDMettler-Toledo International | 6.50x | 5.47% | 59.37% | 26.05% | $1290.84 |
ILMNIllumina Inc | 4.62x | 6.04% | 66.61% | 18.44% | $132.72 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $89.53 |
BIOBio-Rad Laboratories, Inc.Class A | 3.06x | 0.29% | 52.01% | 1.59% | $291.09 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.06x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.75x | 11.57% | 47.13% | 1.40% | $306.06 |
BRKRBruker Corporation | 1.73x | 11.57% | 47.13% | 1.40% | $38.94 |
AVTRAvantor, Inc. | 0.86x | 0.49% | 32.65% | -3.83% | $8.26 |
About
Pacific Biosciences develops and manufactures DNA sequencing platforms that enable genetic analysis for research and clinical applications. The company's integrated technology helps scientists and clinical researchers identify and resolve complex genetic problems. Revenue is generated primarily from the Americas, with significant contributions from Europe, the Middle East, Africa, and Asia-Pacific.